Transcriptomic analyses comparing tumors from MaPR172H/− and MaPR245W/− mice to those of MaP−/− mice revealed (i) dysregulation of unique cancer-associated pathways in tumors and (ii) Nr5a2 (nuclear receptor subfamily 5 group A member 2) as a predicted mediator of mutant-p53 transcriptional programs. This evidence concerns the gene TP53 and cancer.